Primary Description

Also known as:LY3437943GGG tri-agonist

Retatrutide is a novel triple agonist that simultaneously activates three metabolic hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. This unprecedented triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and metabolic health. Clinical trials demonstrate 24.2% body weight reduction at 48 weeks with the 12 mg dose — surpassing all existing obesity medications including tirzepatide (20.9%) and semaglutide (14.9%). The addition of glucagon receptor activation to the GIP/GLP-1 dual agonist approach provides unique metabolic benefits: increased energy expenditure, enhanced fat oxidation, improved hepatic metabolism, and prevention of adaptive metabolic slowdown during weight loss — a key limitation of GLP-1-only agonists. Administered once weekly via subcutaneous injection. Represents the next generation of metabolic therapeutics.

Key Benefits

Weight loss (up to 24%)
Glycemic control
Lipid improvement

Demonstrated Effects

24.2% body weight reduction at 48 weeks — highest ever achieved with pharmacotherapy
Triple receptor activation: GIP + GLP-1 + glucagon for synergistic metabolic effects
Increased energy expenditure via glucagon receptor — prevents metabolic slowdown during caloric restriction
Superior weight loss vs tirzepatide (+3.3%) and semaglutide (+9.3%)
Enhanced fat oxidation and lipolysis
Improved hepatic metabolism and liver fat reduction
Appetite suppression (GLP-1 + GIP mechanisms)
Improved glucose control and insulin sensitivity
Favorable cardiovascular risk factor reduction (lipids, blood pressure)
Potential NASH/NAFLD treatment

Proposed Mechanisms of Action

Proposed mechanisms based on available research

Research Evidence & Clinical Data

Review of available research evidence and clinical data

Investigated Applications

Obesity & Weight Loss

Anecdotal: High

24.2% body weight reduction at 48 weeks with 12 mg dose in Phase 2 trials. Sustained weight loss without the typical metabolic adaptation that limits GLP-1-only approaches. Expected 20–24% body weight reduction in standard protocols.

Preclinical basis: Phase 2 SURMOUNT-1 style trial demonstrated 24.2% weight loss vs 20.9% for tirzepatide and 14.9% for semaglutide. Discontinuation rate of 2.7% comparable to other GLP-1 agonists.

Metabolic Health

Anecdotal: High

Improved glucose control, insulin sensitivity, lipid profiles, and blood pressure. Glucagon receptor activation prevents the adaptive metabolic slowdown seen with GLP-1-only agents during prolonged weight loss.

Preclinical basis: Triple agonism addresses limitations of single and dual agonists. Glucagon component provides metabolic rate maintenance during caloric restriction — a mechanistic advantage over tirzepatide.

Fatty Liver Disease (NASH/NAFLD)

Anecdotal: Medium

Glucagon receptor activation improves hepatic metabolism and reduces liver fat content. Potential therapeutic target for non-alcoholic steatohepatitis.

Preclinical basis: Glucagon receptor agonism directly targets hepatic fat oxidation and metabolism, offering potential benefits for fatty liver disease beyond weight loss alone.

Scientific References

Safety Profile

Common Side Effects

Nausea — 40–50% (most common, usually transient; resolves within 4–8 weeks)
Diarrhea — 25–30%
Vomiting — 15–20%
Constipation — 15–20%
Abdominal pain — 10–15%
Phase 2 discontinuation rate: 2.7% (comparable to other GLP-1 agonists)
Nausea
Diarrhea
Vomiting

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) — theoretical risk
Multiple endocrine neoplasia type 2 (MEN 2 syndrome)
Pregnancy and breastfeeding — insufficient safety data
Severe gastroparesis — may worsen gastric emptying delay
History of pancreatitis — use with caution
MTC history
MEN 2
Pancreatitis

Research Protocols

Dosing protocols based on available research data

Dosing Protocols

Typical Dose

Starting: 2 mg once weekly. Target: 8–12 mg once weekly. Maximum efficacy: 12 mg once weekly.

Frequency

Once weekly, same day each week, any time of day.

Route

Subcutaneous injection. Rotate injection sites: abdomen, thigh, upper arm.

Cycle Length

48+ weeks for maximum weight loss outcomes.

Note: Dose escalation schedule: Weeks 1–4: 2 mg; Weeks 5–8: 4 mg; Weeks 9–12: 6 mg; Weeks 13–16: 8 mg; Weeks 17+: 12 mg (maximum, if tolerated). Slow titration reduces GI side effects. Missed dose: take within 4 days or skip and resume schedule. Storage: refrigerate before first use; can be room temperature after opening. Smaller meals and avoiding fatty foods helps manage GI side effects during titration.

Monitoring & Risk Management

Monitoring guidelines based on available data

No Specific Monitoring Protocol

No structured monitoring data is available for this compound. Always consult a healthcare professional before use.

Health & Research Goals

Retatrutide